Fierce Biotech December 13, 2022
The FDA isn’t the only one with its eye on Cardiosense’s artificial intelligence algorithms, which are aiming to predict heart disease before it develops.
Just a few months after nabbing the regulator’s breakthrough-device designation for the first of those AI models, Cardiosense has rounded up a series A funding round from a handful of investors spanning both the usual VC circles and health system venture funds, the startup announced.
Broadview Ventures and Hatteras Venture Partners led the $15.1 million round, while the Laerdal Million Lives Fund, Portal Innovations and the venture arms of OSF Healthcare and UnityPoint Health also chipped in. Broadview and Hatteras will each send a representative to join Cardiosense’s board of directors.
...Today's Sponsors
Today's Sponsor